BNT162b2 Messenger RNA COVID-19 Vaccine Effectiveness in Patients With Inflammatory Bowel Disease: Preliminary Real-World Data During Mass Vaccination Campaign-Reference-Cited by-同舟云学术

BNT162b2 Messenger RNA COVID-19 Vaccine Effectiveness in Patients With Inflammatory Bowel Disease: Preliminary Real-World Data During Mass Vaccination Campaign

Published:2021-11 Issue:5 Volume:161 Page:1715-1717.e1
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Ben-Tov Amir,Banon Tamar,Chodick Gabriel,Kariv Revital,Assa Amit,Gazit Sivan

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference7 articles.

1. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

2. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

3. SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting

4. Kim JH, et al. Nat Med 27:205–211.

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sustainability: a multifaceted important aspect of cancer care;BJC Reports;2024-03-08

2. BNT162b2 mRNA COVID-19 Vaccine Effectiveness in Patients with Coeliac Disease Autoimmunity: Real-World Data from Mass Vaccination Campaign;Viruses;2023-09-21

3. Efficacy of COVID-19 vaccines in inflammatory bowel disease patients receiving anti-TNF therapy: A systematic review and meta-analysis;Heliyon;2023-09

4. Effects of SARS-CoV-2 vaccine (Vero cells) on disease activity in patients with inflammatory bowel disease in China: a multicenter study;International Journal of Colorectal Disease;2023-02-09

5. SARS-CoV-2 breakthrough infections after COVID-19 vaccination in patients with inflammatory bowel disease: a systematic review and meta-analysis;Therapeutic Advances in Gastroenterology;2023-01